Amneal Pharmaceuticals (AMRX) Tops Q4 EPS by 2c

Amneal Pharmaceuticals (: AMRX) reported Q4 EPS of $0.23, $0.02 better than the analyst estimate of $0.21. Revenue for the quarter came in at $610 million versus the consensus estimate of $579.84 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2023 revenue of $2.25-2.35 billion, versus the consensus of $2.31 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal